Safe Sex Without a Condom: What Actually Works

Multiple evidence-based tools now exist for reducing the risk of both sexually transmitted infections and unintended pregnancy without relying on condoms. Some of these are remarkably effective: daily or injectable PrEP cuts new HIV infections by roughly 90% when used consistently, long-acting contraceptives like IUDs and implants have first-year failure rates around 1%, and a prophylactic antibiotic taken after sex can slash rates of chlamydia and syphilis dramatically. The landscape of “safe sex” has expanded well beyond the condom, though each tool covers a different slice of risk, and no single method yet replaces a condom’s dual protection against both pregnancy and a broad range of infections.

PrEP for HIV Prevention

Pre-exposure prophylaxis, or PrEP, is probably the most significant advance in sexual health in the past two decades. The oral version combines two antiretroviral drugs, tenofovir and emtricitabine, taken as a daily pill. When blood concentrations are consistent with daily dosing, the protective effect against HIV is estimated at around 88 to 91%.¹ The catch is that effectiveness depends heavily on actually taking the medication. Adherence is the single biggest predictor of whether PrEP works or fails.²

For men who have sex with men, an on-demand dosing schedule is also an option. Sometimes called “event-driven PrEP” or the 2-1-1 protocol, it involves taking pills before and after sex rather than every day. A large French cohort study found that HIV incidence on this schedule was just about 1 case per 1,000 person-years, with no difference between daily and on-demand users.³ On-demand PrEP has not been as well studied in other populations, so current guidelines limit this approach to men who have sex with men.

Injectable PrEP is the newer alternative. Cabotegravir, given as an intramuscular shot every two months, sidesteps the adherence problem that plagues daily pills.⁴ In the HPTN 083 trial, injectable cabotegravir reduced HIV incidence by roughly 65 to 69% compared with daily oral PrEP, which was already effective. HIV incidence in the injectable arm was about 0.41 per 100 person-years versus 1.29 for the oral pill during the blinded phase.⁵ The two phase 3 trials testing the injectable were stopped early because it was clearly outperforming the oral option.⁴

Treatment as Prevention

If your partner is living with HIV and taking effective antiretroviral therapy, their medication can be the protection. The principle known as Undetectable = Untransmittable (U=U) means that a person with HIV who achieves and maintains an undetectable viral load has effectively zero risk of sexually transmitting the virus.⁶ This conclusion is backed by large partner studies involving thousands of couples over years. It is not a “probably” or “usually.” When the viral load is undetectable, transmission risk in sexual encounters is zero in the data.

The limitation is verification. U=U requires sustained treatment adherence and regular viral-load monitoring, so it depends on trust and communication between partners. In practice, many people living with HIV have occasional viral load blips, and the protection depends on the load being undetectable at the time of exposure. Still, U=U has fundamentally changed the calculus for serodiscordant couples and is considered established science by every major HIV/AIDS organization.

Doxycycline After Sex for Bacterial STIs

This one is newer and still evolving. Doxycycline post-exposure prophylaxis, known as doxy-PEP, involves taking a 200 mg dose of the antibiotic within 72 hours after condomless sex to prevent bacterial STIs. A landmark trial found that the combined incidence of gonorrhea, chlamydia, and syphilis dropped by about two-thirds in men who took doxycycline after sex compared with those who did not.⁷ The reductions were especially dramatic for chlamydia and syphilis. In the PrEP cohort of that trial, chlamydia risk dropped by about 88% and syphilis by 87%.⁷

A meta-analysis across multiple studies confirmed the broad pattern but added an important caveat: doxy-PEP does not appear to significantly reduce gonorrhea risk.⁸ The pooled data showed roughly a 65% reduction in chlamydia and a 77% reduction in syphilis, but gonorrhea rates were not significantly different. This likely reflects existing antibiotic resistance patterns in gonorrhea. A real-world clinic study in Philadelphia found similar results, with participants experiencing a 62% overall reduction in STI rates while using doxy-PEP.⁹

The concern that hangs over doxy-PEP is antibiotic resistance. Widespread use of doxycycline could accelerate the development of resistance not just in STI-causing bacteria but in other microbes as well. The CDC has endorsed doxy-PEP for men who have sex with men and transgender women who have had a bacterial STI in the past year, but the recommendations are deliberately narrow. For cisgender women, the evidence is less clear, and one trial found the approach did not work well in that population. If you are considering doxy-PEP, it requires a prescription and a conversation with a clinician about whether you fit the profile.

Vaccines That Prevent STIs

Vaccination is the most “set it and forget it” form of STI protection available, though it only covers a few infections. The two established vaccines protect against hepatitis B (HBV) and human papillomavirus (HPV). The HBV vaccine has been available since 1982 and is highly effective, preventing both sexual transmission and the liver disease that chronic infection causes.¹⁰ The HPV vaccine, available since 2006, is about 96% effective against the precancerous cervical lesions caused by the virus, and it also prevents genital warts and anogenital cancers in men.¹¹ Countries with high HPV vaccine uptake are already seeing population-level reductions in infection and precancerous changes, and herd effects are showing up in unvaccinated groups as well.¹⁰

A more surprising development involves the meningococcal B vaccine (4CMenB), originally designed to prevent meningitis. Observational studies from multiple countries found that vaccinated people also had lower rates of gonorrhea, with a pooled vaccine effectiveness of about 32%.¹² The biological rationale makes sense: the bacteria that cause meningitis and gonorrhea are closely related species that share surface proteins. However, three randomized controlled trials in high-risk men who have sex with men failed to show efficacy, creating a frustrating disconnect between the observational and experimental evidence.¹³ Two countries have already rolled out meningococcal B vaccination partly with gonorrhea prevention in mind, but the evidence is clearly muddier than researchers hoped. This remains a space to watch rather than rely on.

Long-Acting Contraception

If your primary concern is pregnancy prevention rather than STIs, the most effective non-condom options are long-acting reversible contraceptives: IUDs and subdermal implants. In real-world use in the United States, both have a first-year failure rate of about 1%, compared with 13% for male condoms and 20% for withdrawal.¹⁴ International data shows even lower failure rates for implants, averaging about 0.6 per 100 users per year across dozens of countries.¹⁵

The reason these methods are so reliable is that they remove human error from the equation. Once an IUD is placed or an implant inserted, there is nothing to remember daily. This is also why there is almost no gap between “perfect use” and “typical use” for these methods, unlike the pill, where perfect use has a failure rate near 0.1% but typical use jumps to somewhere in the range of 3 to 8% because of missed doses.¹⁶ Injectable contraceptives (the shot) sit in the middle, with typical-use failure rates around 1.7 per 100 users internationally.¹⁵

None of these methods protect against STIs. That is the tradeoff. If you are in a mutually monogamous relationship where both partners have been tested, or if you are combining an IUD or implant with an STI-prevention strategy like PrEP or doxy-PEP, the gap is covered. But a long-acting contraceptive on its own is only half the equation for someone with new or multiple partners.

Non-Hormonal Vaginal Options

For people who want to avoid both condoms and hormones, a prescription vaginal pH modulator gel (sold as Phexxi in the U.S.) offers a different approach. Its active ingredients are lactic acid, citric acid, and potassium bitartrate, which maintain vaginal acidity in the presence of semen. Since sperm need an alkaline environment to survive, the gel immobilizes them.¹⁷ It is applied before each act of intercourse, similar to a spermicide, but works through a different mechanism.

The effectiveness numbers are modest compared with long-acting methods. In clinical trials, the cumulative pregnancy rate over six to seven cycles was roughly 4 to 14%, depending on how perfectly users followed the instructions.¹⁸ That puts it in a similar ballpark to condoms and other user-dependent methods. It does not protect against STIs. The appeal is that it is non-hormonal, woman-controlled, and used only when needed, which matters for people who experience side effects from hormonal contraception or who do not want a long-term device.

Withdrawal and Fertility Awareness

These behavioral methods get a bad reputation, and in typical use, that reputation is earned. Withdrawal has a first-year failure rate of about 20% in the U.S. and around 13% internationally, making it one of the least reliable contraceptive approaches.¹⁴ The common fear is that pre-ejaculate contains sperm, and the evidence here is genuinely mixed. One study found that about 41% of men produced pre-ejaculatory fluid containing sperm, with most of those samples including motile sperm.¹⁹ A more recent pilot study of men who routinely practiced perfect-use withdrawal found sperm in only about 13% of pre-ejaculate samples, and most were at concentrations too low to pose a realistic pregnancy risk.²⁰ The discrepancy likely reflects differences in technique and in whether participants had recently ejaculated, which can leave residual sperm in the urethra. Either way, even under the better estimates, withdrawal offers no STI protection and depends entirely on the withdrawing partner’s timing and self-control.

Fertility awareness-based methods involve tracking cycles through temperature, cervical mucus, calendar calculations, or app-based algorithms to identify fertile days and avoid intercourse during them. A systematic review found an average success rate of about 70% across studies, though five of the included studies reported success rates above 90%.²¹ The range is enormous because the effectiveness depends on which specific method is used, how consistently it is followed, and whether users actually abstain or use a backup method during the fertile window. Digital tracking tools have made these methods more accessible, but they have not eliminated the fundamental challenge that ovulation does not always follow a predictable schedule.

The Dapivirine Vaginal Ring

For women in settings where oral PrEP uptake is low, the dapivirine vaginal ring offers an alternative approach to HIV prevention. The ring releases a small amount of an antiretroviral drug over the course of a month. In two large trials, HIV incidence was about 27 to 31% lower in women using the ring compared with placebo.²²²³ That is less impressive than oral or injectable PrEP, but an important detail emerged: protection was much higher in women over 21. In one trial, women over 21 saw a 56% reduction in HIV, while those 21 and younger saw no benefit at all, a pattern that correlated with lower adherence in younger users.²²

In an open-label extension study where women knew they were getting the active ring, the estimated reduction in HIV incidence compared with historical controls was about 39%.²⁴ The ring has been approved by regulators in several African countries and endorsed by the WHO as an additional prevention option. It is not a substitute for PrEP in terms of raw efficacy, but it fills a gap for women who prefer a discreet, self-managed method that does not require daily pill-taking.

The Vaginal Microbiome as a Hidden Variable

One factor that rarely comes up in conversations about safe sex is the vaginal microbiome. A healthy vaginal environment dominated by Lactobacillus bacteria maintains an acidic pH that acts as a natural barrier to many pathogens. When that community is disrupted, as happens in bacterial vaginosis, the prevalence of STIs goes up. One study found that STI prevalence was substantially higher in women with bacterial vaginosis, and co-infections involving multiple STI-causing organisms were significantly more common.²⁵

This has practical implications for other prevention strategies. Research has found that the effectiveness of topical tenofovir gel for HIV prevention varied dramatically by microbiome type: the drug reduced HIV incidence by about 61% in women with Lactobacillus-dominant microbiota but only 18% in women without.²⁶ In other words, the same drug worked three times better depending on the microbial environment it was deployed into. Bacterial vaginosis is extremely common and often asymptomatic, which means many women may be getting less protection from their prevention methods than they expect. Treating recurrent BV and maintaining vaginal health is not usually framed as an STI prevention strategy, but the data suggests it matters more than most people realize.

Layering Methods Together

The real answer to safe sex without a condom is that most people need more than one tool. An IUD prevents pregnancy but not HIV. PrEP prevents HIV but not chlamydia or pregnancy. Doxy-PEP prevents chlamydia and syphilis but not HIV, gonorrhea, or pregnancy. Vaccination covers HPV and hepatitis B but nothing else. Each of these methods addresses a specific threat, and the gaps between them are where risk lives.

A person on PrEP who also uses doxy-PEP and has been vaccinated against HPV and hepatitis B has closed off a large portion of the STI risk landscape without touching a condom. Add an IUD or implant and pregnancy risk drops to about 1%. This layered approach is increasingly common among men who have sex with men and is growing among other populations as awareness expands. The evidence is strong enough for each individual method that combining them is not a stretch. It is, arguably, what the evidence points toward. But it does require engagement with the healthcare system, prescriptions, regular testing, and more planning than rolling on a condom. For people willing to do that work, the protection can be as good as or better than condoms alone for many specific risks.

What Is Coming Next

The pipeline for new methods is busier than it has been in decades. On the male side, several hormonal contraceptive agents are in clinical trials, including combination gels applied to the skin that suppress sperm production while maintaining normal testosterone levels.²⁷ Non-hormonal approaches are also in development, targeting pathways involved in sperm production, motility, and function. Researchers have identified a wide range of molecular targets that could be turned into drugs, though most remain at preclinical stages.²⁸

One approach that gets periodic attention is a reversible vaso-occlusive method, essentially a material injected into the vas deferens to block sperm without cutting it, as a vasectomy does. This concept has been in development in various forms for decades, and versions are in clinical trials in some countries.²⁹ The appeal is that it would be a one-time procedure with years of effectiveness and full reversibility, but progress has been slow. The honest assessment is that a widely available male contraceptive beyond condoms and vasectomy remains years away, despite genuine scientific advances. The factors that matter for any new method go beyond just efficacy: reversibility, safety, how quickly it works, and whether it generates anti-sperm antibodies that could impair future fertility all have to be resolved before anything reaches the market.²⁸

When Emotions Override Risk Assessment

No discussion of safe sex is complete without acknowledging that decisions about protection are not made in a clinical vacuum. Research into sexual decision-making among men who have sex with men found that feelings of love, intimacy, and trust actively reduce how risky people perceive condomless sex to be, and increase willingness to forgo barriers even when people know the biological risks.³⁰ This is not unique to any one population. Across all demographics, the shift from casual encounters to committed relationships tends to coincide with a drop in barrier use, often before both partners have been tested.

This is where the biomedical tools described throughout this article become particularly valuable. If you know that intimacy and trust make you less likely to use condoms, having PrEP, an IUD, up-to-date vaccinations, or a doxy-PEP prescription in place beforehand means the protection is already working before the emotional moment arrives. The best prevention strategy is not the most effective one on paper. It is the one you will actually use consistently, in the relationships and situations where your real life happens.